Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 81, Issue 5 , Pages 309-312 , November 2009

Omega-3 polyunsaturated fatty acids and anxiety disorders

References 

  1. American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 4th Edition.American Psychiatric Publishing Inc., Arlinglton, 1994.
  2. Kalra H, Kamath P, Trivedi KJ, Janca A. Caregiver burden in anxiety disorders. Curr. Opin. Psychiatry. 2008;21:70–73
  3. Batelaan N, Smit F, de Graaf R, van Balkom A, Vollebergh W, Beekman A. Economic costs of full-blown and subthreshold panic disorder. J. Affect Disord. 2007;104:127–136
  4. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25:72–90
  5. Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. Eur. J. Neurol. 2005;12(Suppl 1):39–44
  6. Lépine. JP. The epidemiology of anxiety disorders: prevalence and societal costs. J. Clin. Psychiatry. 2002;63(Suppl 14):4–8
  7. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J. Clin. Psychiatry. 2003;64(Suppl 15):40–45
  8. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch. Gen. Psychiatry. 2005;62:617–627
  9. Nardi AE. Early diagnosis can decrease the social and economic burden of social anxiety disorder. Aust. N Z J. Psychiatry. 2005;39:641–642
  10. Hirschfeld. RMA. The comorbidity of major depression and anxiety disorder: recognition and management in primary care. J. Clin. Psychiatry. 2001;3:244–254
  11. Sartorius N, Ustün TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br. J. Psychiatry. 1996;6(Suppl):38–43
  12. Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, et al. Mental disorders and disability among patients in a primary care group practice. Am. J. Psychiatry. 1997;154:1734–1740
  13. Mayberg H, Liotti M, Brannan S, McGinnis S, Mahurin K, Jerabek P, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am. J. Psychiatry. 1999;156:675–682
  14. Stone EA, Lin Y, Quartermain. D. A final common pathway for depression? Progress toward a general conceptual framework. Neurosci. Biobehav. Rev. 2008;32:508–524
  15. Mitchell PB, Parker GB, Gladstone GL, Wilhelm K, Austin MP. Severity of stressful life events in first and subsequent episodes of depression: the relevance of depressive subtype. J. Affect Disord. 2003;73:245–252
  16. Höschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev. Neurother. 2008;8:537–552
  17. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry. 2000;48:830–843
  18. Peet M, Horrobin. DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry. 2002;59:913–919
  19. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry. 2002;159:477–479
  20. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker. RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am. J. Psychiatry. 2006;163:1098–1100
  21. Su KP, Huang SY, Chiu CC, Shen. WW. A preliminary double-blind, placebo-controlled trial. Omega-3 fatty acids in major depressive disorder. Eur. Neuropsychopharmacol. 2003;13:267–271
  22. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry. 1999;56:407–412
  23. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry. 2006;188:46–50
  24. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry. 2006;67:1954–1967
  25. Ross BM, Senguin J, Sieswerda. L. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids in Health Dis. 2007;6:21
  26. Lin PY, Su. KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry. 2007;68:1056–1061
  27. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85:275–291
  28. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J. Affect Disord. 1996;38:35–46
  29. Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 2003;78:40–46
  30. Frasure-Smith N, Lesperance F, Julien P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol. Psychiatry. 2004;55:891–896
  31. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 PUFA levels in red blood cell membranes of depressive patients. Biol. Psychiatry. 1998;43:315–319
  32. Edwards R, Peet M, Shay J, Horrobin. D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect Disord. 1998;48:149–155
  33. de Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003;7 73:3181–3187
  34. Ross BM. Omega-3 fatty acid deficiency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipid metabolism. Med. Hypotheses. 2007;68:515–524
  35. Hibbeln JR. Seafood consumption, the DHA content of mothers’ milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J. Affect Disord. 2002;69:15–29
  36. Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, Sasaki S, et al. Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br. J. Cancer. 2004;90:787–793
  37. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, et al. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr. Serv. 2001;52:529–531
  38. Iribarren C, Markovitz JH, Jacobs DR, Schreiner PJ, Daviglus M, Hibbeln JR. Dietary intake of n-3, n-6 fatty acids and fish: relationship with hostility in young adults—the CARDIA study. Eur. J. Clin. Nutr. 2004;58:24–31
  39. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:568–575
  40. Moscovitch DA, McCabe RE, Antony MM, Rocca L, Swinson RP. Anger experience and expression across the anxiety disorders. Depress Anxiety. 2008;25:107–113
  41. Fava M. Depression with anger attacks. J. Clin. Psychiatry. 1998;59(Suppl 18):18–22
  42. van Praag HM. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr. Scand. Suppl. 1998;393:81–88
  43. Green P, Hermesh H, Monselise A, Marom S, Presburger G, Weizman A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur. Neuropsychopharmacol. 2006;16:107–113
  44. Muntaner C, Eaton WW, Miech R, O'Campo P. Socioeconomic position and major mental disorders. Epidemiol. Rev. 2004;26:53–62
  45. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest Dermatol. 1992;98:812–815
  46. Katzman M, Cornacchi S, Coonerty-Femiano A, Hughes B, Vermani M, Struzik L, et al. Methyl nicotinate-induced vasodilation in generalized social phobia. Neuropsychopharmacology. 2003;28:1846–1851
  47. Ross BM, Ward P, Glen I. Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder. J. Affect Disord. 2004;82:285–290
  48. Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J. Lipid Res. 2003;44:1984–1991
  49. Song C, Li X, Kang Z, Kadotomi. Y. Omega-3 fatty acid ethyl-eicosapentaenoate attenuates IL-1beta-induced changes in dopamine and metabolites in the shell of the nucleus accumbens: involved with PLA2 activity and corticosterone secretion. Neuropsychopharmacology. 2007;32:736–744
  50. Hamilton. M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50–55
  51. Yehuda S, Rabinovitz S, Mostofsky DI. Mixture of essential fatty acids lowers test anxiety. Nutr. Neurosci. 2005;8:265–267
  52. Emken EA, Adlof RO, Gulley RM. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim. Biophys. Acta. 1994;1213:277–288
  53. Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Masatoshi T, et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial. Nutrition. 2005;21:705–710
  54. Zeev K, Michael M, Ram K, Hagit C. Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disorder patients. Neuropsychiatr. Dis. Treat. 2005;1:187–190
  55. Fux M, Benjamin J, Nemets. B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J. Psychiatr. Res. 2004;38:323–325
  56. Buydens-Branchey L, Branchey M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J. Clin. Psychopharmacol. 2006;26:661–665
  57. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32:568–575

PII: S0952-3278(09)00174-4

doi: 10.1016/j.plefa.2009.10.004

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 81, Issue 5 , Pages 309-312 , November 2009

Article Tools